Arax Advisory Partners Has $3.79 Million Position in Abbott Laboratories $ABT

Key Points

• Arax Advisory Partners cut its Abbott Laboratories stake by 45% in the fourth quarter, leaving it with 30,247 shares worth about $3.79 million.
• Abbott reported better-than-expected quarterly results, with EPS of $1.15 and revenue of $11.16 billion, and it reiterated FY2026 guidance of $5.38 to $5.58 per share.
• Despite the earnings beat, several analysts lowered price targets on ABT, and the stock was trading below both its 50-day and 200-day moving averages.

Arax Advisory Partners lowered its position in Abbott Laboratories (NYSE:ABT - Free Report) by 45.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,247 shares of the healthcare product maker's stock after selling 24,735 shares during the period. Arax Advisory Partners' holdings in Abbott Laboratories were worth $3,790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Abbott Laboratories in the fourth quarter worth $2,938,892,000. Invesco Ltd. lifted its position in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. Ninety One UK Ltd bought a new position in Abbott Laboratories in the fourth quarter worth $336,815,000. Vanguard Group Inc. lifted its position in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares during the period. Finally, Stifel Financial Corp lifted its position in Abbott Laboratories by 122.0% in the fourth quarter. Stifel Financial Corp now owns 3,947,686 shares of the healthcare product maker's stock worth $494,610,000 after purchasing an additional 2,169,184 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company's stock, valued at $201,300. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel J. Starks bought 10,000 shares of the company's stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $87.89 on Monday. The firm has a 50-day moving average of $91.46 and a 200-day moving average of $107.84. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a market cap of $153.08 billion, a PE ratio of 24.62, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ABT shares. JPMorgan Chase & Co. dropped their price objective on Abbott Laboratories from $123.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, April 17th. Piper Sandler lowered their price objective on Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Oppenheimer lowered their price objective on Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. BofA decreased their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday. Finally, Wells Fargo & Company cut their price objective on Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $118.38.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.